Fildena is an India-market sildenafil name associated with Fortune Healthcare product catalogs. Unlike a simple single-tablet trade name, Fildena is advertised with conventional tablets, a CT chewable range, Super Active softgel capsules and strength-named extensions such as Double and Extra Power. These descriptions involve different claimed forms and must not be collapsed into one U.S.-approved sildenafil formulation.
Fortune Healthcare Product Private Limited lists Fildena 100 tablets, Fildena CT 100 chewables, a CT 50 entry, Fildena Super Active softgels and higher-strength listings. Importantly, several online catalog entries mix product names or report conflicting ingredients and strengths in adjacent fields. A structured, documented claim can be described, but inconsistent catalog data cannot validate the exact composition of every variant.
This is a brand-record guide, not a prescription, efficacy ranking or foreign-pharmacy ordering page. The focus is what can actually be learned from Fildena-specific listings and what remains uncertain. For FDA-approved U.S. sildenafil see generic sildenafil products; for the other India-market names visit the Indian brands directory.
The table separates conventional tablet names from claimed chewable and capsule presentations. “Company catalog listing” means the name and basic claimed format appear on a Fortune-linked product page, not that the formulation has an independently verified regulatory approval or clinical effect. Some entries have errors that prevent confident extraction of every field.
Fildena is therefore best studied by exact product suffix and composition. The presence of the same ingredient in two advertised products does not establish comparable absorption, interchangeability or approved substitution.
| Fildena name | Claimed contents / presentation | Evidence boundary |
|---|---|---|
| Fildena 100 | Sildenafil 100 mg conventional tablet | Fortune-linked catalog; pack-level verification still required |
| Fildena CT 100 | Sildenafil 100 mg chewable tablet | Company entry explicitly identifies a chewable form |
| Fildena CT 50 | Advertised 50 mg chewable sildenafil | Catalog card contains conflicting unrelated-brand fields; do not rely on all specifications |
| Fildena Super Active | Sildenafil softgel capsules, described at 100 mg | Form listed; companion dosage text is inconsistent |
| Fildena Extra Power | Advertised sildenafil 150 mg tablets | Non-U.S.-labeled strength; claim from catalog |
| Fildena Double | Advertised sildenafil 200 mg tablet | Product description conflicts with some generic dosage fields |
| Fildena Strong 120 | Strength-labelled sildenafil name | One online card contains unrelated tadalafil details; unresolved composition |
Fortune Healthcare business sites describe the company as a manufacturer, supplier and exporter and name Fildena among products they promote. Their storefront records support a commercial association and some product-name claims. They are not, however, a replacement for an authenticated finished-product license, original label or batch-release documentation.
Some records also offer third-party manufacturing. That is why the exact company role on a specific Fildena pack should be described as “manufacturer,” “marketer” or “supplier” only when evidence supports it. A company name on an export page alone is not proof of the physical manufacturing site for every branded form.
The Fildena CT 50 and Strong 120 entries are examples of data problems: headlines refer to one Fildena presentation while nearby structured fields refer to another brand or another ingredient, including tadalafil. Those combinations cannot all describe the same finished product. They may reflect copy-and-paste product-card errors rather than verified changes to the medicine.
A careful account should therefore keep the headline claim separate from the disputed fields and withhold a definitive strength-and-composition statement until labeling is reviewed. This is a more informative conclusion than silently correcting the vendor page or building a seemingly exact product table from contradictory information.
The CT 100 listing explicitly describes a sildenafil citrate chewable tablet. This provides a reason to treat CT as a form-specific product description, not an alternative spelling for a standard swallowed tablet. Marketing terms about convenience do not independently establish clinical onset or whether the presentation can be substituted for a U.S.-approved tablet.
For a patient comparing prescriptions, the relevant facts are the full ingredient, approved dosage form and actual prescription instructions. The sildenafil administration page discusses U.S. labeled tablet use; it does not validate foreign-market chewable directions.
Fortune-linked listings name Fildena Super Active as sildenafil softgel capsules, often using a 100 mg headline. Adjacent dosage strings sometimes include other amounts, so the catalog does not establish a coherent complete capsule lineup. Claims that a softgel necessarily acts faster or causes fewer adverse effects have not been demonstrated merely by the formulation name.
A softgel and a conventional tablet can differ in formulation even with the same ingredient amount. It would be misleading to merge Super Active into the ordinary Fildena tablet table or to attribute U.S. Viagra labeling to it.
Names such as Extra Power and Double are marketed with unusually high strengths in Fortune-related listings, including 150 and 200 mg. The names are promotional and do not indicate an FDA-sanctioned ED regimen. They also do not show that the medicine is more effective than approved U.S. products.
U.S. Viagra ED tablet presentations are labeled at 25, 50 and 100 mg. That distinction is explained in the U.S. product-strength guide. Actual clinician-directed dosing, adverse-effect considerations and interacting drugs belong to the dosing guide, not to a foreign brand’s marketing suffix.
The evidence supports a brand-company association and identifies several names in company-linked sales catalogs. It does not verify every photographed package, purported therapeutic-equivalence claim or a consistent ingredient record for the conflicting listings. The appropriate distinction is “catalogued name,” “catalogued form,” and “fully identified medicine.” These are not interchangeable categories.
For a specific pack, original packaging and independently meaningful regulatory identifiers would be needed to resolve composition and company roles. An online store listing a low price or fast delivery says nothing about approval; this page intentionally provides neither prices nor ordering offers.
FDA product authorization is product-specific. Fildena’s appearance in Indian export catalogs does not establish a U.S. application or therapeutic-equivalence listing for the named products. A U.S. clinician may prescribe an approved sildenafil ED medicine, but that fact is not transferable to Fildena CT, softgel or high-strength variants.
Read Viagra brand identity and FDA-approved generics for the regulated U.S. market. International ingredient similarity alone is not an approved substitution pathway.
Any verified sildenafil ingredient involves important risks with nitrates and riociguat, among other precautions. The possibility of an incorrectly described capsule or chewable adds an identity concern before any individual medical assessment can even begin. People should not use higher-strength foreign-product claims to select their own dose.
Importing unapproved medicines is generally prohibited under U.S. law except for narrow discretionary circumstances. The appropriate domestic process is clinical evaluation and dispensing of an approved prescription drug by a licensed pharmacy, explained in the U.S. buying guide.
Fildena’s distinctive research issue is the inconsistent Fortune-linked catalog and the CT, Super Active, Double and Extra Power subfamilies. By contrast, Cenforce has its own Centurion-linked listings, while Kamagra has a separately documented Ajanta-marketed Indian tablet. The mere presence of sildenafil in these brands does not establish that their differently marketed dosage forms can be substituted.
The correct comparison begins with a documented finished product, not a claim that every brand is a different strength of a single generic medicine. For the ingredient-wide picture use the sildenafil hub.
Fildena is an India-market brand family associated with sildenafil in Fortune Healthcare catalogs, including conventional tablets and other advertised forms.
Yes. Fortune-linked company listings name Fildena 100 as a sildenafil tablet, although individual product packs and company roles still warrant verification.
CT is used on catalogued Fildena chewable products, including a CT 100 entry. A chewable should not automatically be treated like a standard U.S. sildenafil tablet.
No. It is marketed as a softgel capsule presentation. Its product description includes inconsistent dosage details that limit precise conclusions.
Not by the available catalog descriptions. Some high-strength cards contain conflicting fields; they should remain unconfirmed until reliable labeling is available.
No. Promotional strength names do not establish superior effectiveness, safe self-adjustment or U.S. regulatory approval.
The identified foreign-market Fildena listings do not demonstrate FDA approval for those specific products.
Importing unapproved prescription drugs is generally unlawful; U.S. patients should use a clinician and licensed pharmacy for approved prescriptions.